Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression

Therapeutic Drug Monitoring

Volumn 29, Issue 6, 2007, Pages 824-834

  Ferreirós, Nerea ^a,b   Dresen, Sebastian ^a   Alonso, Rosa María ^b   Weinmann, Wolfgang ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Angiotensin II receptor antagonists; Ion suppression; Liquid chromatography tandem mass spectrometry; Validation

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; EPROSARTAN; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FORENSIC SCIENCE; GAS CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; HUMANS; IONS; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 36549056206     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815d0f66     Document Type: Article

References (35)

1. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med. 1995;155:1361-1368.
2. Plosker GL, Foster RH. Eprosartan: a review of its use in the management of hypertension. Drugs. 2000;60:177-201.
3. Lo MW, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995;58:641-649.
4. Domenic AS, Todd WB. Ghosh G, et al. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44:797-814.
5. Fenton C, Scott LJ. Candesartan cilexetil: a review of its use in the management of chronic heart failure. Drugs. 2005;65:537-558.
6. Croom KF, Curran MP, Goa KL, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64:999-1028.
7. Robins GW, Scott LJ. Eprosartan: a reviewof its use in the management of hypertension. Drugs. 2005;65:2355-2377.
8. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs. 2006;66:51-83.
9. Wagstaff AJ. Valsartan/Hydrochlorothiazide: a review of its use in the management of hypertension. Drugs. 2006;66:1881-1901.
10. Hillaert S, Van den Bossche W. Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-IIreceptor antagonists. J Chromatogr. 2002;979:323-333.
11. Hillaert S, Van den Bossche W. Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis. J Pharm Biomed Anal. 2003;31:329-339.
12. Hillaert S, De Beer TR, De Beer JO, et al. Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists. J Chromatogr. A 2003;984:135-146.
13. Gonzalez L, Alonso RM, Jiménez RM. A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine. Chromatographia. 2000;52:735-740.
14. Cagigal E, Gonzalez L, Alonso RM, et al. Experimental design methodologies to optimise the spectrofluorimetric determination of losartan and valsartan in human urine. Talanta. 2001;54:1121-1133.
15. Gonzalez L, Lopez JA, Alonso RM, et al. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorometric detection. J Chromatogr. 2002;949:49-60.
16. Torrealday N, Gonzalez L, Alonso RM, et al. Experimental design approach for the optimisation of a HPLC-fluorometric method for the quantitation of the angiotensin II receptor antagonist telmisartan in urine. J Pharm Biomed Anal. 2003;32:847-857.
17. Lundberg DE, Person RC, Knox S, et al. Determination of SK&F 108566 (Teveten®) in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr. 1998;707:328-333.
18. Kondo T, Yoshida K, Yoshimura Y, et al. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization. J Mass Spectrom. 1996;31:873-878.
19. Krieter PA, Colletti AE, Millar RR, et al. Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. J Pharmacol Exper Ther. 1995;273:816-822.
20. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol. 2000;56:135-140.
21. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005;45:68-78.
22. Oliveira CH, Silva RM, Santagada V, et al. Comparative bioavailability of two losartan formulations in healthy human volunteers after a single dose administration. Int J Clin Pharmacol Ther. 2006;44:142-148.
23. Iwasa T, Takano T, Hara K, et al. Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr. 1999;734:325-330.
24. Polinko M, Rifle K, Song H, et al. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal. 2003;33:73-84.
25. Chen B, Liang Y, Wang Y, et al. Development and validation of liquid chromatography-mass spectrometry method for the determination of telmisartan in human plasma. Anal Chim Acta. 2005;540:367-373.
26. Li P, Wang Y, Wang Y, et al. Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr. 2005;828:126-129.
27. Dresen S, Kempf J, Weinmann W. Electrospray-ionization MS/MS library of drugs as database for method development and drug identification. Forensic Sci Int. 2006;161:86-91.
28. Hubert P, Chiap P, Crommen J, et al. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory. Anal Chim Acta. 1999;391:135-148.
29. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, CDER, 2001.
30. Aderjan R, Babel B, Briellmann T, et al. Forensic guidelines of the German Society of Toxicological and Forensic Chemistry, March 28, 2000. Available at: http://www.gtfch.org/tk/tk67_1/akqual.pdf. Accessed May 15, 2007.
31. Matuszewski BK, Constanzer ML, Chavez-eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030.
32. Bonfiglio R, King RC, Olah TV, et al. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom. 1999;13:1175-1185.
33. Müller C, Schaefer P, Stoertzel M, et al. Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J Chromatogr. 2002;773:47-52.
34. Shen JX, Motyka RJ, Roach JP, et al. Minimization of ion suppression in LC-MS/MS analysis through the application of strong cation exchange solid-phase extraction (SCX-SPE). J Pharm Biomed Anal. 2005;37:359-367.
35. Nie J, Zhang M, Fan Y, et al. Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine. J Chromatogr. 2005;828:62-69.